Related Experiment Video
Updated: Sep 29, 2025
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
Killing SCLC: insights into how to target a shapeshifting tumor
Kate D Sutherland1,2, Abbie S Ireland3, Trudy G Oliver3
1Australian Cancer Research Foundation (ACRF) Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Abstract:
Small cell lung cancer (SCLC) is a rapidly growing, highly metastatic, and relatively immune-cold lung cancer subtype. Historically viewed in the laboratory and clinic as a single disease, new discoveries suggest that SCLC comprises multiple molecular subsets. Expression of MYC family members and lineage-related transcription factors ASCL1, NEUROD1, and POU2F3 (and, in some studies, YAP1) define unique molecular states that have been associated with distinct responses to a variety of therapies. However, SCLC tumors exhibit a high degree of intratumoral heterogeneity, with recent studies suggesting the existence of tumor cell plasticity and phenotypic switching between subtype states. While SCLC plasticity is correlated with, and likely drives, therapeutic resistance, the mechanisms underlying this plasticity are still largely unknown. Subtype states are also associated with immune-related gene expression, which likely impacts response to immune checkpoint blockade and may reveal novel targets for alternative immunotherapeutic approaches. In this review, we synthesize recent discoveries on the mechanisms of SCLC plasticity and how these processes may impinge on antitumor immunity.
Insights
Small cell lung cancer (SCLC) is not a single disease but has multiple subtypes. Understanding SCLC plasticity and its impact on immune response is crucial for developing new cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Small cell lung cancer (SCLC) is an aggressive, metastatic cancer.
- SCLC is increasingly recognized as a heterogeneous disease with distinct molecular subtypes.
- These subtypes are defined by specific transcription factors and impact therapeutic responses.
Purpose of the Study:
- To review recent discoveries on the mechanisms driving SCLC plasticity.
- To explore how SCLC plasticity influences antitumor immunity.
- To identify potential therapeutic targets for SCLC.
Main Methods:
- Literature review of recent studies on SCLC molecular subtypes and plasticity.
- Analysis of gene expression patterns associated with SCLC subtypes.
- Synthesis of data on the relationship between SCLC plasticity and immune evasion.
Main Results:
- SCLC comprises multiple molecular subsets defined by transcription factor expression (e.g., ASCL1, NEUROD1, POU2F3, YAP1).
- Intratumoral heterogeneity and tumor cell plasticity are key features of SCLC.
- SCLC plasticity is linked to therapeutic resistance and influences immune gene expression.
Conclusions:
- SCLC plasticity is a critical factor in therapeutic resistance.
- Understanding SCLC plasticity mechanisms can reveal novel immunotherapeutic targets.
- Further research into SCLC plasticity is essential for improving patient outcomes.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...